Titan Pharmaceuticals, Inc.

NasdaqCM:TTNP

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💻 Telehealth

Location

United States

Market Cap

USD 5.85 M

Share Price

USD 4.40

Avg Daily Volume

41,631

Change (1 day)

0.00%

Change (1 year)

-20.72%

Change (YTD)

34.97%

Titan Pharmaceuticals, Inc. Share Price on June 27, 2025: USD 4.40

Titan Pharmaceuticals, Inc. Share Price is USD 4.40 on June 27, 2025, a -20.72% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Titan Pharmaceuticals, Inc. 52-week low Share Price is USD 10.00 on June 27, 2025, which is 127.27% above the current Share Price.
Titan Pharmaceuticals, Inc. 52-week low Share Price is USD 3.15 on June 27, 2025, which is -28.41% below the current Share Price.
Titan Pharmaceuticals, Inc. average Share Price for the last 52 weeks is USD 4.43.

Daily

From:

To:

Zoom:

Key data

Date	Share Price	Share Price	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)

NasdaqCM: TTNP

Titan Pharmaceuticals, Inc.

CEO	Mr. Weei Jye Chay
IPO Date	Jan. 18, 1996
Location	United States
Headquarters	400 Oyster Point Boulevard
Employees	4
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💻 Telehealth

Description

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.